Heart transplant breakthrough? OCS device Follow-Up study tracks 5-Year survival

NCT ID NCT05741723

Ongoing Disease control Sponsor: TransMedics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 276 heart transplant patients who received a donor heart preserved with the OCS Heart device. Researchers will track survival and other outcomes for up to 5 years after transplant. The goal is to confirm the long-term safety and effectiveness of using OCS-preserved hearts for transplantation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCS Heart device (preserves donor hearts for transplant)
What this could lead to: If successful, this study could confirm that OCS-preserved hearts are safe and effective for transplantation, potentially increasing the donor heart supply.
What could go wrong: This is a follow-up study, not a new treatment test. It only observes outcomes in already transplanted patients, so it cannot prove new benefits or safety beyond what is already known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART TRANSPLANT

Contacts and locations

Locations

AdventHealth Orlando

Orlando, Florida, 32803, United States
Duke University

Durham, North Carolina, 27710, United States
Emory University Hospital

Atlanta, Georgia, 30322, United States
Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Minneapolis Heart Institute

Minneapolis, Minnesota, 55407, United States
Montefiore

The Bronx, New York, 10467, United States
Northwestern Medicine

Chicago, Illinois, 60611, United States
Nyph/Cumc

New York, New York, 10032, United States
Sentara

Norfolk, Virginia, 23502, United States
St. Vincent Cardiovascular Research Institute

Indianapolis, Indiana, 46260, United States
Stanford University

Palo Alto, California, 94304, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
University of California San Diago

La Jolla, California, 92037, United States
University of Minnesota

Minneapolis, Minnesota, 55414, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Wisconsin

Madison, Wisconsin, 53792, United States
Vanderbilt Medical Center

Nashville, Tennessee, 37232, United States
Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.